Works matching IS 1007385X AND DT 2022 AND VI 29 AND IP 2
1
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 157, doi. 10.3872/j.issn.1007-385x.2022.02.011
- Article
2
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 142, doi. 10.3872/j.issn.1007-385x.2022.02.009
- Article
3
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 150, doi. 10.3872/j.issn.1007-385x.2022.02.010
- Article
4
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 135, doi. 10.3872/j.issn.1007-385x.2022.02.008
- Article
5
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 128, doi. 10.3872/j.issn.1007-385x.2022.02.007
- Article
6
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 120, doi. 10.3872/j.issn.1007-385x.2022.02.006
- Article
7
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 114, doi. 10.3872/j.issn.1007-385x.2022.02.005
- Article
8
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 108, doi. 10.3872/j.issn.1007-385x.2022.02.004
- Article
9
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 93, doi. 10.3872/j.issn.1007-385x.2022.02.002
- Article
10
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 87, doi. 10.3872/j.issn.1007-385x.2022.02.001
- Article
11
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 2, p. 101, doi. 10.3872/j.issn.1007-385x.2022.02.003
- Article